

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmttd.org/>

## Original Research Article

## Study of prevalence and antimicrobial susceptibility pattern of blood culture isolates from a tertiary care hospital in South India

Iqra Anjum<sup>1</sup>, Maimoona Mustafa<sup>1,\*</sup><sup>1</sup>Dept. of Microbiology, Deccan College of Medical Sciences, Hyderabad, Telangana, India

## ARTICLE INFO

## Article history:

Received 03-06-2023

Accepted 17-05-2023

Available online 23-09-2023

## Keywords:

Bloodstream infections

bacteremia

Extended Spectrum BLactamases

MetalloBLactamase

## ABSTRACT

**Background:** Bloodstream infections progress rapidly to life threatening septicemia and sepsis and hence appropriate rapid management is crucial.**Materials and Methods:** A prospective study was carried out in the department of microbiology where patients with clinical suspicion of bacteremia were enrolled and blood culture was performed. The isolates were identified by phenotypic characters and antimicrobial susceptibility performed.**Results:** A total of 1200 blood samples were collected out of which 279 were positive for aerobic bacterial growth. *Staphylococcus aureus* was the most commonly isolated organism followed by *Klebsiella*, *Escherichia coli* and *Pseudomonas aeruginosa*. Gentamicin (81.6%), Levofloxacin (75%), Meropenem (88.5%) and *Piperacillin-tazobactam* (93.8%) showed higher sensitivities when compared to Cephalosporins (55%-68%) and penicillin.**Conclusion:** Gram-negative bacteria have high resistance rates and discordant antibiotic treatment can lead to multi-organ involvement. Proper timely institution of empirical treatment and adherence to antimicrobial stewardship guidelines coupled with aggressive management is crucial in saving lives.This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Blood Stream Infections (BSI) are defined as presence of bacteria in the blood; which can range from inapparent bacteraemia to fulminant septic shock with high mortality.

The invasion of microorganisms in the bloodstream-intermittently or continuously pose a major threat to every organ in the body can lead to serious consequences like shock, multi-organ failure, Disseminated Intravascular Coagulation and death.

Sepsis is defined as the presence of viable multiplying bacteria in the bloodstream and production of toxins. Patients with bloodstream infections manifest clinically with systemic signs of infection such as fever, leukocytosis and raised inflammatory markers. BSI could be primary

due to spread from infective endocarditis, Urinary Tract Infection (UTI), or Community acquired pneumonia, or secondary resulting from device associated infections or surgical interventions.

Blood culture is the yard-stick for identification of these pathogens. However empirical antimicrobial therapy is crucial in preventing unchecked progression to sepsis.<sup>1</sup>

The choice of Automated Manual Transmission (AMT) depends on the likely source of infection and the causative organism. Empirical therapy can be narrowed down to a single antibiotic agent once the causing agent is isolated and the antimicrobial susceptibility testing is performed.<sup>2</sup>

It is important to consider the resistance pattern of each species for better treatment of infections caused by resistant microorganisms.

\* Corresponding author.

E-mail address: [maimoonamustafa@gmail.com](mailto:maimoonamustafa@gmail.com) (M. Mustafa).

## 2. Materials and Methods

### 2.1. Study duration and sample

A prospective study was carried out between January 2022 to February 2023 in a Tertiary care Hospital in Hyderabad, India. A total of 1200 patients with clinical suspicion of bacteraemia were enrolled after obtaining the consent.

### 2.2. Inclusion and exclusion criteria

Patients aged  $\geq 2$  years were included while neonates and those with history of Antibiotic intake <72 hours earlier were excluded from the study. Patients suspected to have viral or parasitic infections, tuberculosis and those with autoimmune disease and on steroids were excluded.

### 2.3. Specimen collection and processing

Blood was collected via venipuncture from a peripheral vein (preferably Antecubital vein) under strict aseptic conditions and inoculated appropriately into labelled adult and paediatric blood culture bottles, respectively. These were loaded into BD BACTEC-9050 Blood Monitoring System and incubated at 37°C. Positively flagged Blood Cultures were further processed via direct Gram's stain and inoculation onto solid media.

A subculture was performed onto Nutrient, MacConkey and 5% Sheep Blood Agar plates and incubated overnight at 37°C. The isolate was identified based on colony morphology, Grams staining and biochemical properties as per standard protocols.<sup>3</sup> Antimicrobial susceptibility testing of the isolated bacteria was performed using Kirby-Bauer disk diffusion method and the results interpreted as per the CLSI 2022 guidelines.<sup>4</sup> Quality control was carried out by testing each new batch of media and antibiotics using standard strain. Cefozolin was used as a surrogate marker for testing cefpodoxime, cefuroxime and cefdinir.<sup>4</sup>

The Gram-Positive cocci, *Staphylococcus* species were tested for methicillin resistance using 30µg Cefoxitin disc with served as a surrogate marker for Methicillin resistance. A zone size of  $\leq 21$  was considered as *MecA* positive, MRSA.<sup>4</sup> Quality control was performed using control MRSA strain ATCC 43300.

Gram Negative bacilli obtained were subjected to detection of ESBL production using Cefotaxime 30µg and Cefotaxime-clavulanate 30/10µg disc.<sup>4</sup> Quality control was performed using *Klebsiella pneumoniae* ATCC 700603.

Gram Negative isolates were screened for imipenem resistance. Imipenem resistant isolates were further tested for Metallo-β-Lactamase production using Imp-EDTA combined disc as described by Yong et. al.<sup>5</sup>


The data and the results were obtained in the Microsoft Excel and statistically analysed. Multi-drug resistant bacteria were identified and percentages of MDR were calculated.

## 3. Results

279 (23.25%) aerobic bacterial isolates were obtained from paediatric and adult patients with clinical suspicion of bacteraemia. The spectrum of isolates obtained and their frequency are depicted in Table 1 and diagrammatic presentation in Figure 1. 108 (38.71%) isolates were Gram positive cocci while 171(61.29%) were Gram negative bacilli. 5 fungal isolates were also obtained during the study.

**Table 1:** Frequency of bacterial isolates.

| Organism                         | Frequency (n) | Percentage |
|----------------------------------|---------------|------------|
| Gram positive bacteria           | <b>n=108</b>  |            |
| <i>Staphylococcus aureus</i>     | 63            | 58.3%      |
| Coagulase Negative Staphylococci | 14            | 12.9%      |
| <i>Enterococcus</i> species      | 26            | 24%        |
| <i>Streptococcus pyogenes</i>    | 2             | 1.8%       |
| <i>Streptococcus viridans</i>    | 3             | 2.7%       |
| Gram negative bacteria           | <b>n=171</b>  |            |
| <i>Escherichia coli</i>          | 38            | 22.22%     |
| <i>Klebsiella</i> species        | 42            | 24.56%     |
| Enterobacter                     | 14            | 8.18%      |
| <i>Pseudomonas aeruginosa</i>    | 38            | 22.22%     |
| <i>Acinetobacter</i> species     | 34            | 19.88%     |
| Salmonella species               | 4             | 2.3%       |
| <i>Citrobacter freundii</i>      | 1             | 0.5%       |
| Fungi                            | <b>n=5</b>    |            |
| <i>Candida</i> species           | 5             |            |



**Fig. 1:** Frequency of bacterial isolates.

*Staphylococcus aureus* was the most common isolate followed by *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Acinetobacter* and *Enterococcus* species. Antimicrobial susceptibility pattern for Gram positive and Gram-negative isolates was interpreted and is displayed in Tables 2 and 3. 24.37% of all isolates were MDR. A bacterial isolate is said to be multi-drug resistant when it tests resistant to at least one (1) antimicrobial agent from three separate antimicrobial classes.<sup>6</sup> *Klebsiella spp.* and *Enterobacter spp.* showed 28.56% multi-drug resistant strains each.

**Table 2:** Drug sensitivity profile of Gram-negative isolates. (%)

|                                | <i>Escherichia coli</i><br>(n=38) | <i>Klebsiella spp.</i><br>(n=42) | <i>Enterobacter Cloaca</i> (n=14) | <i>Acinetobacter spp.</i> (n=34) | <i>Pseudomonas aeruginosa</i> (n=38) |
|--------------------------------|-----------------------------------|----------------------------------|-----------------------------------|----------------------------------|--------------------------------------|
| Ampicillin                     | 26.67                             | -NT-                             | -NT-                              | -NT-                             | –                                    |
| Ampicillin-sulbactam           | 35.29                             | 61                               | -NT-                              | 56.25                            | –                                    |
| Cefoxitin                      | 29.41                             | 44.44                            | –                                 | –                                | –                                    |
| Cefozolin                      | 45.45                             | 41.67                            | -NT-                              | –                                | –                                    |
| Co-trimoxazole                 | 58.82                             | 46.15                            | 66.67                             | 83                               | –                                    |
| Aztreonam                      | 52.94                             | 64.29                            | 66.67                             | -NT-                             | 58.33                                |
| Amikacin                       | 50                                | 70.00                            | 75                                | 88.89                            | 81.81                                |
| Gentamicin                     | 90                                | 75.00                            | –                                 | 80.00                            | –                                    |
| Levofloxacin                   | 60                                | 81.25                            | –                                 | 77.78                            | 81.25                                |
| Cefotaxime                     | 47.06                             | 53.33                            | 66.67                             | 80                               | –                                    |
| Cefatazidime                   | 43.75                             | 61.54                            | 66.67                             | 58.33                            | 61.11                                |
| Cefepime                       | 55                                | 62.50                            | 57.14                             | 81.25                            | 84.61                                |
| Meropenem                      | 78.26                             | 77.78                            | 100                               | 93.33                            | 93.33                                |
| <i>Piperacillin-tazobactam</i> | 93.75                             | 83.33                            | 100                               | 100                              | 92.30                                |
| MDR%                           | 21                                | 28.5                             | 28.5                              | 17.6                             | 10.5                                 |

**Table 3:** Drug-sensitivity profile of Gram-positive isolates (%)

|                       | <i>Staphylococcus spp.</i>                        |                                 | Coagulase negative<br>(n=16) | <i>Enterococcus</i> (n=26) |
|-----------------------|---|---------------------------------|------------------------------|----------------------------|
|                       | Coagulase positive<br>Methicillin sensitive(n=38) | Methicillin Resistant<br>(n=25) |                              |                            |
| Penicillin            | 25  | 25                              | 19.14                        | 50                         |
| Azithromycin          | 57.71   | 50                              | 21.15                        | –                          |
| Clindamycin           | 58.33   | 75                              | 55.76                        | –                          |
| Erythromycin          | 16.67   | 12.5                            | 31.57                        | –                          |
| Doxycycline           | 100   | 90                              | 92.59                        | –                          |
| Ciprofloxacin         | 91.66   | 75                              | 76                           | 81.81                      |
| Rifampicin            | 100   | 100                             | 84                           | –                          |
| Cotrimoxazole         | 90  | 85                              | 66.67                        | –                          |
| Vancomycin            | 100   | 100                             | 95                           | 100                        |
| Linezolid             | 100   | 100                             | 100                          | 100                        |
| High-level gentamicin | –   | –                               | –                            | 80                         |
| MDR %                 | 14.2  | 25.4                            | –                            | –                          |

#### 4. Discussion

Blood stream infections are a life-threatening condition and timely diagnosis and rapid appropriate institution of antimicrobials is crucial in saving lives. Antibiotic resistance rates keep constantly increasing and has become a major public health threat; responsible for 1.27 million deaths worldwide.<sup>7</sup> 20% of the cases of BSI have been reported to receive discordant empirical antimicrobial therapy; i.e. administration of antibiotics to the patient which later tested resistant on performing antimicrobial susceptibility testing.<sup>8</sup> Infection with an antibiotic resistant pathogens (e.g. *Pseudomonas aeruginosa*) is more associated with discordant therapy with increased mortality rates; even in patients without sepsis.<sup>8</sup>

Hence adherence to antibiogram is necessary to as local bacterial communities and their antibiotic susceptibility

patterns differ widely and appropriate empirical treatment is crucial.

In our study Gram negative bacteria predominated as the causative agents of BSI; accounting for 61% of the bacterial isolates and 39% Gram Positive cocci. Banik et al<sup>9</sup> reported 57% Gram negative isolates while Khurana et. al had GNB amounting to 77% in 2013; 85% in 2014 and 81% in 2015 & 2016.<sup>10</sup>

*Staphylococcus aureus* was the single most common isolate amounting to 58.3% of all Gram-positive isolates. 39.68% of *S. aureus* were Methicillin Resistant *Staphylococcus aureus* (MRSA). Similarly, 42% *S. aureus* 59% methicillin resistance was noted by Banik. et. al.<sup>9</sup>

Vancomycin, linezolid, doxycycline and rifampicin showed good action for both MSSA and MRSA; however, it has been recommended that Rifampicin should not be used as single drug therapy for treatment.<sup>4</sup>

Doxycycline is has 90% oral bio-availability as it is highly lipophilic and can easily cross various biological membranes to reach target site in both Gram positive and negative bacteria.<sup>11</sup> Doxycycline should be preferred to Linezolid as although both have high oral bioavailability but Doxycycline is more cost-effective. Vancomycin is available as I.V. preparations and as contrary to previous recommendations,<sup>11</sup> recent studies highlight the advantage of oral preparations to treat bloodstream infections in patients with uncomplicated bacteraemia.<sup>12</sup> And hence doxycycline can be used as alternative to Vancomycin and linezolid in immunocompetent patients.

Coagulase Negative *Staphylococci* are usual skin commensals but are being increasingly recognised as pathogenic bacteria in certain settings especially in the presence of any risk factor; namely presence of central venous catheter, immunocompromised status, and metabolic disorders. 12.9% of the Gram-positive isolates in our study comprised CONS while other studies by Vasudeva et. al.<sup>13</sup> reported 30% of GPC isolates to be CONS and Banik et. al.<sup>9</sup> reported 23.31% CONS.

We considered CONS as the pathogenic organism based on clinical presentation, procalcitonin levels and wherever possible reisolating the same strain on subsequent blood culture. Improper technique of blood collection; coupled with existence of long-standing intravascular devices are recognised as possible routes of spread of CONS into the bloodstream. CONS were highly susceptible to doxycycline, Ciprofloxacin, Linezolid and Vancomycin while penicillin, azithromycin, erythromycin, and clindamycin showed poor response. All Gram-positive isolates were susceptible to Linezolid.

While the incidence of Enterococcal Bloodstream infections varies considerably<sup>12,13</sup> ranging from 5% as observed by Banik et al.<sup>9</sup> to 8% in Meshram et al<sup>14</sup> in we had a higher incidence of Enterococcal Blood stream infections; contributing to 24% of GPCs and 9.3% of total bacterial isolates with high susceptibility towards linezolid, vancomycin, ciprofloxacin and high-level gentamicin; however considerable resistance towards penicillin was demonstrated by Enterococcal isolates.

61% of the total isolates were Gram-negative bacteria. The Gram-negative isolates obtained showed high resistance towards penicillin and ampicillin-sulbactam indicating reduced efficacy of these drugs.

*Klebsiella* was the most common GNB isolated. Vasudeva et al<sup>13</sup> had *E. coli* as the commonest GNB while Banik et al<sup>9</sup> has *Acinetobacter* followed by *Klebsiella spp.*

*Klebsiella pneumoniae* and *Escherichia coli* showed decreased susceptibility to cephalosporins as well as cephamycins. *Piperacillin-Tazobactam* and Gentamicin had good sensitivities against GNB. 39% of the isolates showed production of Extended spectrum  $\beta$ -Lactamases, with 52% of the *Escherichia coli* being ESBL producers.

Significant number of isolates were positive for Metallo- $\beta$ -Lactamase production with 21.7% of *E. coli* and 22.22% of *K. Pneumoniae* being positive for MBL production.

Previous studies highlight high frequency of prevalence of MDR *Klebsiella pneumoniae* with 30-day mortality rate as high as 45% in patients with *K. pneumoniae* BSI.<sup>15,16</sup> 28% of *Klebsiella* and 21% *E. coli* were detected to be multi drug resistant strains. *Klebsiella pneumoniae* is notorious for its ability to accumulate and transfer resistance determinants, and it has been well-recognized as a leading causative agent of hospital-based infections over the previous decades.

Non-Enterobacteriaceae Gram Negative bacilli have been implicated to cause 43-58% of BSI.<sup>10</sup> In our study these amounted to 43.8% of the total isolates with high incidence of *Pseudomonas aeruginosa*, i.e., 50.6% of the non-Fermenting bacteria (n=38) and *Acinetobacter spp.* Being 45.3%; (n=34) *P. aeruginosa* is a major cause of Hospital-associated infections; in our study the isolates were moderately resistant to Aztreonam and ceftazidime and showing good susceptibility (>80%) to Aminoglycosides; fluoroquinolones (i.e. levofloxacin), carbapenems and *Piperacillin-tazobactam*. Micek et al.<sup>17</sup> in their study entitled "*Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment" state that mortality in patients with *P. aeruginosa* infections is statistically higher in patients receiving discordant empirical therapy and is reduced in patients who receive combination therapy than monotherapy.<sup>17</sup>

*Acinetobacter* species in our study were sensitive to Meropenem (93%), *piperacillin-tazobactam* (100%) and 4<sup>th</sup> generation cephalosporins (84%). One isolate of Carbapenem-Ampicillin Sulbactam Resistant (CASR) *Acinetobacter baumannii* was isolated. Infection with CASR *A. baumannii* was observed to be associated with increased severity of infection and high mortality.<sup>18,19</sup>

## 5. Conclusion

Bloodstream infections are a medical emergency and antibiotics are central and pivotal in saving lives. Judicial usage of antibiotics while preventing antibiotic misuse is a challenge especially in severely ill patients. Adherence to Hospital antibiogram and antimicrobial stewardship policy can help tackle this situation.

## 6. Conflict of Interest

The authors declare that there is no conflict of interest.

## 7. Source of Funding

None.


## Acknowledgements

None.

## References

- Washington JA. Blood cultures: principles and techniques. *Mayo Clin Proc.* 1975;50(2):91–8.
- Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med.* 2010;362(19):1804–13. doi:10.1056/NEJMra0904124.
- Collee JG, Digicid JP, Fraser AG. Mackie & McCartney practical medical microbiology. 14th edn. New York: Churchill Livingstone; 1996.
- Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility testing. 30th edn. CLSI supplement M100, Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
- Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y, et al. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol.* 2002;40(10):3798–801. doi:10.1128/JCM.40.10.3798-3801.2002.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2011;18(3):268–81. doi:10.1111/j.1469-0691.2011.03570.x.
- Christopher JL, Murray M. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet.* 2022;399(10325):629–55. doi:10.1016/S0140-6736(21)02724-0.
- Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Adjemian J; forming the National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI). Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. *Lancet Infect Dis.* 2021;21(2):241–51. doi:10.1016/S1473-3099(20)30477-1.
- Banik A, Bhat SH, Kumar A, Palit A, Sneha K. Bloodstream infections and trends of antimicrobial sensitivity patterns at Port Blair. *J Lab Physicians.* 2018;10(3):332–7. doi:10.4103/JLP.JLP\_50\_18.
- Khurana S, Bhardwaj N, Kumari M, Malhotra R, Mathur P. Prevalence, etiology, and antibiotic resistance profiles of bacterial bloodstream infections in a tertiary care hospital in Northern India: A 4-year study. *J Lab Physicians.* 2018;10(4):426–31. doi:10.4103/JLP.JLP\_78\_18.
- Patel RS, Parmar M. DoxycyclineHyclate. [Updated 2022 Jul 12]. vol. 2022. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK555888/>.
- Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;49(1):1–45. doi:10.1086/599376.
- Vasudeva N, Nirwan PS, Shrivastava P. Bloodstream infections and antimicrobial sensitivity patterns in a tertiary care hospital of India. *TherAdv Infect Dis.* 2016;3(5):119–27. doi:10.1177/2049936116666983.
- Meshramp G, Gedam D, Ambhore N, Karyakarte R. Blood stream infections-prevalence in a tertiary care institute, Central India. *Indian J Microbiol Res.* 2018;5(1):87–91.
- MFarhadi, Ahanjan M, Goli HR. High frequency of multidrug-resistant (MDR) *Klebsiella pneumoniae* harboring several  $\beta$ -lactamase and integron genes collected from several hospitals in the north of Iran. *Ann Clin Microbiol Antimicrob.* 2021;20:70. doi:10.1186/s12941-021-00476-1.
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis.* 2011;53(3):285–92. doi:10.1093/cid/cir034.
- Micek S, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. *Antimicrob Agents Chemother.* 2005;49(4):1306–11. doi:10.1128/AAC.49.4.1306-1311.2005.
- Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing *Klebsiella pneumoniae*. *Crit Care.* 2020;24:29. doi:10.1186/s13054-020-2742-9.
- Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, et al. Epidemiology of bloodstream infections caused by *Acinetobacter baumannii* and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. *Antimicrob Agents Chemother.* 2013;57(12):6770–5. doi:10.1128/AAC.01520-13.

## Author biography

Iqra Anjum, Senior Resident  <https://orcid.org/0009-0004-5654-0126>

Maimoona Mustafa, Professor and HOD

**Cite this article:** Anjum I, Mustafa M. Study of prevalence and antimicrobial susceptibility pattern of blood culture isolates from a tertiary care hospital in South India. *IP Int J Med Microbiol Trop Dis* 2023;9(3):145-149.